Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | PORCN | Q9H237 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776252 | 0.85 | CYP2D6 (0.44) | PORCNCYP2D6NPC1RAB9ARPS6KA3 | |
| SCHEMBL20631618 | 0.84 | ABL1 (0.36) | ABL1PORCNCYP2D6FGFR4CYP11B2 | |
| SCHEMBL16776107 | 0.83 | RAB9A (0.37) | FGFR4CYP11B2NPC1RAB9AFAAH | |
| SCHEMBL16776059 | 0.82 | CYP11B2 (0.37) | FGFR4CYP11B2NPC1RAB9AFAAH | |
| SCHEMBL19670344 | 0.81 | FGFR4 (0.35) | ABL1PORCNCYP2D6FGFR4CYP11B2 | |
| SCHEMBL16776151 | 0.81 | BRD4 (0.36) | FGFR4NPC1RAB9AFAAH | |
| SCHEMBL16776016 | 0.81 | WNT3A (0.40) | ABL1PORCNCYP11B2 | |
| SCHEMBL16776133 | 0.81 | FAAH (0.38) | FGFR4FAAH | |
| SCHEMBL16776186 | 0.80 | CYP11B2 (0.41) | ABL1FGFR4CYP11B2FAAH | |
| SCHEMBL16776136 | 0.80 | FAAH (0.41) | CYP2D6FGFR4FAAHRPS6KA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ABL1 4089/4885PORCN 3797/4885CYP2D6 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.